Robotic versus laparoscopic hepatectomy for liver malignancies (ROC'N'ROLL)

• Verfasst von: Birgin, Emrullah [VerfasserIn]
• Verfasst von: Heibel, Marie [VerfasserIn]
• Verfasst von: Hetjens, Svetlana [VerfasserIn]
• Verfasst von: Rasbach, Erik [VerfasserIn]
• Verfasst von: Reißfelder, Christoph [VerfasserIn]
• Verfasst von: Téoule, Patrick [VerfasserIn]
• Verfasst von: Rahbari, Nuh Nabi [VerfasserIn]
• Titel: Robotic versus laparoscopic hepatectomy for liver malignancies (ROC'N'ROLL)
• Titelzusatz: a single-centre, randomised, controlled, single-blinded clinical trial
• Verf.angabe: Emrullah Birgin, Marie Heibel, Svetlana Hetjens, Erik Rasbach, Christoph Reissfelder, Patrick Téoule, and Nuh N. Rahbari
• E-Jahr: 2024
• Jahr: August 2024
• Umfang: 11 S.
• Fussnoten: Online verfügbar: 24. Juni 2024, Artikelversion: 1. August 2024 ; Gesehen am 04.02.2025
• Titel Quelle: Enthalten in: The lancet. Regional health
• Ausgabe Quelle: Europe
• Ort Quelle: [Amsterdam] : Elsevier, 2021
• Jahr Quelle: 2024
• Band/Heft Quelle: 43(2024) vom: Aug., Artikel-ID 100972, Seite 1-11
• ISSN Quelle: 2666-7762
• DOI: doi:10.1016/j.lanepe.2024.100972
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: DaVinci®
• Sach-SW: Liver resection
• Sach-SW: Minimally invasive hepatectomy
• Sach-SW: Randomized controlled trial
• Sach-SW: Robot-assisted
• K10plus-PPN: 1916304745

Abstract

Background - Robotic hepatectomy (RH) has been increasingly adopted for the treatment of liver malignancies despite lacking evidence from randomised trials. We aimed to determine the effect of RH compared to laparoscopic hepatectomy (LH) on quality of life in patients undergoing minimally invasive hepatectomy for liver malignancies. - Methods - This single-blinded, randomised trial was conducted at a tertiary care academic centre (DRKS00027531). Patients with resectable liver malignancies were assessed for eligibility and randomly assigned to either RH or LH with stratification by type of malignancy and difficulty of resection. Patients were blinded to the treatment allocation. The primary outcome was the mean quality of life within 90 days after surgery, measured with the role functioning scale of the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Secondary outcomes included operating time, morbidity, blood loss, conversion rate, postoperative recovery, and resection margin status. - Findings - Between February 21, 2022, and Sep 18, 2023, 80 patients (RH: n = 41, LH: n = 39) were included and analysed on an intention-to-treat basis. Role functioning scores did not differ between RH and LH (mean [SD], 74.3 [23.3] versus 79.6 [22.3]; mean difference −5.3, 95% CI −15.6 to 5.1, p = 0.547). The comprehensive complication index was not significantly different between the study groups (8.9 [23.1] versus 15.5 [23.9], p = 0.137). There were no differences in other perioperative outcomes. - Interpretation - RH yielded similar outcomes in quality of life and can be considered a safe alternative to LH. - Funding - None.